Cargando…

Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model

INTRODUCTION: Gene therapy have recently attracted much attention as a curative therapeutic option for inherited single gene disorders such as hemophilia. Hemophilia is a hereditary bleeding disorder caused by the deficiency of clotting activity of factor VIII (FVIII) or factor IX (FIX), and gene th...

Descripción completa

Detalles Bibliográficos
Autores principales: Noda, Masashi, Tatsumi, Kohei, Matsui, Hideto, Matsunari, Yasunori, Sato, Takeshi, Fukuoka, Yasushi, Hotta, Akitsu, Okano, Teruo, Kichikawa, Kimihiko, Sugimoto, Mitsuhiko, Shima, Midori, Nishio, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441024/
https://www.ncbi.nlm.nih.gov/pubmed/34584911
http://dx.doi.org/10.1016/j.reth.2021.08.009
_version_ 1783752791399858176
author Noda, Masashi
Tatsumi, Kohei
Matsui, Hideto
Matsunari, Yasunori
Sato, Takeshi
Fukuoka, Yasushi
Hotta, Akitsu
Okano, Teruo
Kichikawa, Kimihiko
Sugimoto, Mitsuhiko
Shima, Midori
Nishio, Kenji
author_facet Noda, Masashi
Tatsumi, Kohei
Matsui, Hideto
Matsunari, Yasunori
Sato, Takeshi
Fukuoka, Yasushi
Hotta, Akitsu
Okano, Teruo
Kichikawa, Kimihiko
Sugimoto, Mitsuhiko
Shima, Midori
Nishio, Kenji
author_sort Noda, Masashi
collection PubMed
description INTRODUCTION: Gene therapy have recently attracted much attention as a curative therapeutic option for inherited single gene disorders such as hemophilia. Hemophilia is a hereditary bleeding disorder caused by the deficiency of clotting activity of factor VIII (FVIII) or factor IX (FIX), and gene therapy for hemophilia using viral vector have been vigorously investigated worldwide. Toward further advancement of gene therapy for hemophilia, we have previously developed and validated the efficacy of novel two types of gene transfer technologies using a mouse model of hemophilia A. Here we investigated the efficacy and safety of the technologies in canine model. Especially, validations of technical procedures of the gene transfers for dogs were focused. METHODS: Green fluorescence protein (GFP) gene were transduced into normal beagle dogs by ex vivo and in vivo gene transfer techniques. For ex vivo gene transfer, blood outgrowth endothelial cells (BOECs) derived from peripheral blood of normal dogs were transduced with GFP gene using lentivirus vector, propagated, fabricated as cell sheets, then implanted onto the omentum of the same dogs. For in vivo gene transfer, normal dogs were subjected to GFP gene transduction with non-viral piggyBac vector by liver-targeted hydrodynamic injections. RESULTS: No major adverse events were observed during the gene transfers in both gene transfer systems. As for ex vivo gene transfer, histological findings from the omental biopsy performed 4 weeks after implantation revealed the tube formation by implanted GFP-positive BOECs in the sub-adipose tissue layer without any inflammatory findings, and the detected GFP signals were maintained over 6 months. Regarding in vivo gene transfer, analyses of liver biopsy samples revealed more than 90% of liver cells were positive for GFP signals in the injected liver lobes 1 week after gene transfers, then the signals gradually declined overtime. CONCLUSIONS: Two types of gene transfer techniques were successfully applied to a canine model, and the transduced gene expressions persisted for a long term. Toward clinical application for hemophilia patients, practical assessments of therapeutic efficacy of these techniques will need to be performed using a dog model of hemophilia and FVIII (or FIX) gene.
format Online
Article
Text
id pubmed-8441024
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Japanese Society for Regenerative Medicine
record_format MEDLINE/PubMed
spelling pubmed-84410242021-09-27 Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model Noda, Masashi Tatsumi, Kohei Matsui, Hideto Matsunari, Yasunori Sato, Takeshi Fukuoka, Yasushi Hotta, Akitsu Okano, Teruo Kichikawa, Kimihiko Sugimoto, Mitsuhiko Shima, Midori Nishio, Kenji Regen Ther Original Article INTRODUCTION: Gene therapy have recently attracted much attention as a curative therapeutic option for inherited single gene disorders such as hemophilia. Hemophilia is a hereditary bleeding disorder caused by the deficiency of clotting activity of factor VIII (FVIII) or factor IX (FIX), and gene therapy for hemophilia using viral vector have been vigorously investigated worldwide. Toward further advancement of gene therapy for hemophilia, we have previously developed and validated the efficacy of novel two types of gene transfer technologies using a mouse model of hemophilia A. Here we investigated the efficacy and safety of the technologies in canine model. Especially, validations of technical procedures of the gene transfers for dogs were focused. METHODS: Green fluorescence protein (GFP) gene were transduced into normal beagle dogs by ex vivo and in vivo gene transfer techniques. For ex vivo gene transfer, blood outgrowth endothelial cells (BOECs) derived from peripheral blood of normal dogs were transduced with GFP gene using lentivirus vector, propagated, fabricated as cell sheets, then implanted onto the omentum of the same dogs. For in vivo gene transfer, normal dogs were subjected to GFP gene transduction with non-viral piggyBac vector by liver-targeted hydrodynamic injections. RESULTS: No major adverse events were observed during the gene transfers in both gene transfer systems. As for ex vivo gene transfer, histological findings from the omental biopsy performed 4 weeks after implantation revealed the tube formation by implanted GFP-positive BOECs in the sub-adipose tissue layer without any inflammatory findings, and the detected GFP signals were maintained over 6 months. Regarding in vivo gene transfer, analyses of liver biopsy samples revealed more than 90% of liver cells were positive for GFP signals in the injected liver lobes 1 week after gene transfers, then the signals gradually declined overtime. CONCLUSIONS: Two types of gene transfer techniques were successfully applied to a canine model, and the transduced gene expressions persisted for a long term. Toward clinical application for hemophilia patients, practical assessments of therapeutic efficacy of these techniques will need to be performed using a dog model of hemophilia and FVIII (or FIX) gene. Japanese Society for Regenerative Medicine 2021-09-10 /pmc/articles/PMC8441024/ /pubmed/34584911 http://dx.doi.org/10.1016/j.reth.2021.08.009 Text en © 2021 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Noda, Masashi
Tatsumi, Kohei
Matsui, Hideto
Matsunari, Yasunori
Sato, Takeshi
Fukuoka, Yasushi
Hotta, Akitsu
Okano, Teruo
Kichikawa, Kimihiko
Sugimoto, Mitsuhiko
Shima, Midori
Nishio, Kenji
Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title_full Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title_fullStr Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title_full_unstemmed Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title_short Development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
title_sort development of alternative gene transfer techniques for ex vivo and in vivo gene therapy in a canine model
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441024/
https://www.ncbi.nlm.nih.gov/pubmed/34584911
http://dx.doi.org/10.1016/j.reth.2021.08.009
work_keys_str_mv AT nodamasashi developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT tatsumikohei developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT matsuihideto developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT matsunariyasunori developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT satotakeshi developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT fukuokayasushi developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT hottaakitsu developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT okanoteruo developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT kichikawakimihiko developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT sugimotomitsuhiko developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT shimamidori developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel
AT nishiokenji developmentofalternativegenetransfertechniquesforexvivoandinvivogenetherapyinacaninemodel